Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L Hauser

Showing results (221-230 of 322) with videos related to

Pageof 33
Sort By:
Brain : a Journal of Neurology|December 29, 2020
Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosisKicheol Kim, Anne-Katrin Pröbstel, Ryan Baumann, et al.
JCI Insight|February 13, 2019
Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosisAriele L Greenfield, Ravi Dandekar, Akshaya Ramesh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 29, 2025
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosisTjalf Ziemssen, Mark S Freedman, Amit Bar-Or, et al.
The Journal of Clinical Investigation|November 20, 2012
B cell exchange across the blood-brain barrier in multiple sclerosisH-Christian von Büdingen, Tracy C Kuo, Marina Sirota, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Plos One|August 4, 2020
Imaging correlates of visual function in multiple sclerosisEduardo Caverzasi, Christian Cordano, Alyssa H Zhu, et al.
Nature|August 9, 2019
Opposing T cell responses in experimental autoimmune encephalomyelitisNaresha Saligrama, Fan Zhao, Michael J Sikora, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Pageof 33

Showing results (221-230 of 322) with videos related to

Sort By:
Pageof 33
Brain : a Journal of Neurology|December 29, 2020
Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosisKicheol Kim, Anne-Katrin Pröbstel, Ryan Baumann, et al.
JCI Insight|February 13, 2019
Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosisAriele L Greenfield, Ravi Dandekar, Akshaya Ramesh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 29, 2025
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosisTjalf Ziemssen, Mark S Freedman, Amit Bar-Or, et al.
The Journal of Clinical Investigation|November 20, 2012
B cell exchange across the blood-brain barrier in multiple sclerosisH-Christian von Büdingen, Tracy C Kuo, Marina Sirota, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Plos One|August 4, 2020
Imaging correlates of visual function in multiple sclerosisEduardo Caverzasi, Christian Cordano, Alyssa H Zhu, et al.
Nature|August 9, 2019
Opposing T cell responses in experimental autoimmune encephalomyelitisNaresha Saligrama, Fan Zhao, Michael J Sikora, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Pageof 33